| |
[摘要]：In this issue of Blood, Juarez and colleagues reveal a need for the Sphingosine-1-Phosphate/S1P receptor 1 (S1P/S1P(1)) axis in the egress of hematopoietic stem cells/hematopoietic progenitor cells (HSCs/HPCs) from the bone marrow after CXCR4 antagonist mediated mobilization in mice.(1) The authors also demonstrate an additional peripheral blood stern cell (PBSC) mobilization benefit for SIP1 agonist co-treatment in combination with a CXCR4 antagonist (see figure) but not human granulocyte colony-stimulating factor (G-CSF). |
|
